Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study".

In fact, the phase Ib/IIa study showed a trend toward dose dependence for reductions in iPTH and corrected calcium at evocalcet doses up to 12 mg in hemodialysis patients, although there was a limitation that the number of patients in the 8 and 12 mg groups was small [ 3 ].

also in 53,322 other papers